Skip to main content
Equibles
VRDN logo

VRDN · Viridian Therapeutics, Inc.\DE · Investor Relations

Track VRDN — free

Use VRDN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research VRDN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$18.34 +0.06 (+0.33%)
Russell 2000 member Rebalance outlook locked
Market Cap
$2.07B
Shares
113.29M
Volume · Oct 8 2.44M Avg daily vol (3M) 1.71M

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Recent news

Date Headline
2026-09-02 Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference
2026-08-06 Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results
2026-06-26 Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease
2026-05-27 Viridian Therapeutics to Participate in Upcoming June Investor Conferences
2026-05-07 Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million
2026-05-05 Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock
2026-05-05 Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress
2026-05-05 Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease
2026-03-30 Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease
2026-02-26 Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results
2026-01-08 Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-01-06 Viridian Therapeutics Prepares for Transformational 2026
2025-12-22 Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease

Past events

Date Event Type
2026-09-08 Wells Fargo 21st Annual Healthcare Conference Conference
2026-06-29 Lumvoa™ (veligrotug-vvze) FDA Approval Event
2026-06-09 Goldman Sachs 47th Annual Global Healthcare Conference Conference
2026-06-03 Jefferies Global Healthcare Conference Conference
2026-05-05 Earnings conference call (announced in 8-K) Earnings call
2026-03-30 REVEAL-1 Phase 3 Topline Results Event
2026-03-09 Leerink Partners Global Healthcare Conference Conference
2026-03-04 TD Cowen 46th Annual Health Care Conference Conference
2025-12-04 8th Annual Evercore Healthcare Conference Conference
2025-11-19 Jefferies Global Healthcare Conference in London Conference
2025-11-12 Stifel 2025 Healthcare Conference Conference
2025-06-09 Goldman Sachs Global Healthcare Conference Conference
2025-06-04 Jefferies Global Healthcare Conference Conference
2025-05-20 RBC Global Healthcare Conference Conference
2025-03-12 Leerink Global Healthcare Conference Conference
2025-03-03 TD Cowen Health Care Conference Conference
2024-12-16 THRIVE-2 Phase 3 Topline Results Event
2024-09-09 Thrive Phase 3 Topline Results Event
2024-05-08 Viridian Therapeutics First Quarter 2024 Earnings Call Earnings call
2023-12-18 Subcutaneous IGF-1R program selection Event

Source: https://investors.viridiantherapeutics.com/overview/default.aspx

Key facts CIK 1590750 CUSIP 92790C104 13F (30d) 4 filings 4 filers Visit website Investor relations